Amgen $28.5 billion Horizon Therapeutics acquisition financing
We advised the lender parties on the financing
Davis Polk is advising the lender parties in connection with a $28.5 billion senior unsecured bridge loan facility for Amgen Inc. The facility will be available to Amgen to pay a portion of the cash consideration for its acquisition of Horizon Therapeutics PLC, an Irish public limited company, and to pay related transaction fees and expenses.
Amgen is one of the world’s leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses.
The Davis Polk finance team includes partners Jason Kyrwood and Nick Benham, counsel Benjamin Cheng, Randy Dorf and Aaron Ferner, associates Catalina Ford, Roxanne Walton and Joshua Bunn. Partner John B. Meade is providing capital markets advice. Members of the Davis Polk team are based in the New York, Washington DC and London offices.